Phase 2 Alzheimer's Disease Trial, Recruiting NCT05446584 Sponsor: University of Texas Southwestern Medical Center Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT05446584
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a type of mild memory and thinking problem called mild cognitive impairment (the "amnestic" type)
  • You either have a history of a mild traumatic brain injury (such as a concussion) OR you have no such history — both groups may be included
  • Both women and men can take part
  • People of all racial and ethnic backgrounds are welcome
  • You are 55 years of age or older
  • You can speak and understand English fluently

Who may not be able to join:

  • You had a mild traumatic brain injury (such as a concussion) within the past year
  • You have ever had a moderate or severe brain injury at any point in your life
  • You have ever been diagnosed with a major brain or nervous system condition, such as a stroke, epilepsy, or a brain tumor
  • You have ever had a major heart condition, such as a heart attack or heart failure
  • You are currently struggling with a substance use disorder (for example, alcohol or drug dependency)
  • You currently have a major mental health condition, such as severe depression or bipolar disorder
  • You currently have vision or hearing problems that would make it difficult to complete the study tests
  • You have any metal or electronic implants in your skull or brain (for example, certain types of medical devices)
  • You are currently taking medication known to affect how the brain responds to a specific type of mild electrical brain stimulation used in this study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 214-865-9508

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
20 April 2023
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Changes in Rey Auditory Verbal Learning Test Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov